Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Keytruda
Keytruda
With big Keytruda and Opdivo data coming at AACR, analyst hands Merck the early edge
Fierce Pharma
Fri, 04/13/18 - 12:55 pm
Merck
Bristol-Myers Squibb
Keytruda
Opdivo
Yervoy
AACR
Merck's stock surges after positive Keytruda trial results
Marketwatch
Mon, 04/9/18 - 09:32 am
Merck
Keytruda
clinical trials
metastatic non-small cell lung cancer
Merck gets a lift, Pfizer a ding as analysts assess immuno-oncology, M&A outlook
Fierce Pharma
Fri, 04/6/18 - 11:49 am
Merck
Pfizer
immuno-oncology
M&A
Keytruda
Prevnar
Ibrance
Xeljanz
Xtandi
Incyte's stock plunges, Merck shares fall after disappointing study results of melanoma treatment
Marketwatch
Fri, 04/6/18 - 09:51 am
Incyte
Merck
melanoma
epacadostat
Keytruda
clinical trials
metastatic melanoma
Preliminary positive results for Phase I - II trial of Tesaro's Zejula with Keytruda in platinum-resistant ovarian cancer (TSRO)
CP Wire
Mon, 03/26/18 - 02:48 pm
Tesaro
Zejula
Merck
Keytruda
platinum-resistant ovarian cancer
niraparib
clinical trials vaccines
Preliminary positive results for Phase I - II trial of Tesaro's Zejula with Keytruda in platinum-resistant ovarian cancer
Mon, 03/26/18 - 02:41 pm
Tesaro
Zejula
Merck
Keytruda
platinum-resistant ovarian cancer
niraparib
clinical trials
Roche's Tecentriq triumphs in squamous lung cancer. Can it make its mark against Merck?
Fierce Pharma
Tue, 03/20/18 - 03:27 pm
Roche
Tecentriq
squamous non-small cell lung cancer
Merck
Keytruda
Merck's Keytruda shows up its rivals with NICE backing in bladder cancer
Fierce Pharma
Fri, 03/16/18 - 09:18 pm
Merck
Keytruda
NICE
bladder cancer
Incyte study could bring lessons for cancer immunotherapy
Biopharma Dive
Wed, 03/14/18 - 11:27 am
Incyte
cancer immunotherapy
metastatic melanoma
Merck
Keytruda
[video]How Convenience Can Give Drugmakers a Competitive Edge
Motley Fool
Tue, 03/13/18 - 10:08 am
convenience
Merck
Bristol-Myers Squibb
dosing
Opdivo
Keytruda
Doubling down on the Keytruda franchise, Merck pays $300M and promises $5B-plus to partner with Eisai on its budding cancer star
Endpoints
Thu, 03/8/18 - 09:42 am
Merck
Keytruda
Eisai
Lenvima
Merck says Keytruda's explosive growth prompts need for new Ireland plant with 350 jobs
Fierce Pharma
Wed, 02/14/18 - 11:33 am
Merck
Keytruda
Ireland
hirings
drug manufacturing
Merck quarterly profit beats on Keytruda demand
Yahoo/Reuters
Fri, 02/2/18 - 09:41 am
Merck
earnings
Keytruda
5 Highest-Growth Drugs of 2018 -- and Who Will Get Rich from Them
Motley Fool
Sun, 01/21/18 - 10:53 am
Merck
Keytruda
AbbVie
Humira
Mavyret
Bristol-Myers Squibb
Eliquis
Pfizer
Ibrance
Merck & Co.’s shares rise over 7% thanks to new positive clinical results from Keytruda
GoinPharma
Wed, 01/17/18 - 09:44 pm
Merck
Keytruda
non-squamous cell non-small cell lung cancer
Merck & Co. and Eisai seek to undermine BMS’ position in kidney cancer treatment sector
GoinPharma
Wed, 01/17/18 - 10:05 am
Eisai
Merck
Bristol-Myers Squibb
kidney cancer
Keytruda
Lenvima
Opdivo
Merck's Keytruda extends lung cancer survival in combination trial
Yahoo/Reuters
Tue, 01/16/18 - 10:01 am
Merck
Keytruda
lung cancer
clinical trials
Merck's Keytruda nabs new data to rival Bristol-Myers' Opdivo at fending off melanoma's return
Fierce Pharma
Mon, 01/15/18 - 10:37 am
Merck
Keytruda
Bristol-Myers Squibb
Opdivo
melanoma
Merck, Eisai nab Keytruda-Lenvima 'breakthrough' in quickly crowding kidney cancer field
Fierce Pharma
Fri, 01/12/18 - 06:39 pm
Merck
Eisai
Keytruda
Lenvima
kidney cancer
Cancer Space Update: New Regulatory Status for 3 Major Drugs
Yahoo/Zacks.com
Fri, 01/5/18 - 05:33 pm
cancer
Merck
Japan
Keytruda
Seattle Genetics
Adcetris
Novartis
Kisqali
Pages
« first
‹ previous
…
14
15
16
17
18
19
20
21
22
…
next ›
last »